EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2030

Conditions
Lung CancerEGFR Gene Mutation
Interventions
DEVICE

Circulating Tumor DNA (ctDNA) Assay

Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.

Trial Locations (6)

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

NOT_YET_RECRUITING

Massachusetts General Hospital, Boston

02135

NOT_YET_RECRUITING

Dana-Farber Cancer Institute at Steward St. Elizabeth's, Brighton

01844

NOT_YET_RECRUITING

Dana-Farber Cancer Instiute Merrimack Valley, Methuen

02190

NOT_YET_RECRUITING

Dana-Farber Cancer Institute South Shore, South Weymouth

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Boston Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER